Follow up | Frequency No (%) |
Increasing dose (600 - 800 mg) | 10 (18.5) |
Decreased dose (100 - 300) | 5 (9.2) |
Transformation to acute & accelerated phase | 7 (13) |
Death | 4 (7) |
Discontinued imatinib | 9 (16) |
Complete hematologic response | 94% |
Molecular response | 46.8% |
Refer for transplantation | 2 (3.3) |
Median duration follow up | 44 (8 - 115) month |
Unknown cases | 6 (10) |